Study finds PTSD interacts with Klotho gene, may cause premature aging in the brain
Genetics and the environment (including psychiatric stress) may contribute to the pace of cellular aging, causing some individuals to have a biological age that exceeds their chronological age.

Klotho VS Variant Preserves Memory by Preventing Tangles
Researchers are beginning to uncover genetic factors that modify the ability of amyloid plaques to spur tau pathology. Now, scientists led by Michael Ewers at Ludwig-Maximilians University, Munich, add a longevity gene into the mix.

Klotho Variant Cuts ApoE4’s Alzheimer Risk by a Third
A meta-analysis of 22 cohorts seems to leave little doubt that variants of the longevity gene klotho protect against dementia—at least in people unfortunate enough to have inherited an ApoE4 allele.

Human and Mouse Microglia React Differently to Amyloid
Transgenic mice fail to capture many aspects of Alzheimer’s disease, and a new transcriptional study lays bare one reason. Brain cells in the two species, it turns out, respond quite differently to amyloidosis

Anti-aging protein hormone Klotho shown to be neuroprotective in ALS model
Increasing the levels of the anti-aging protein hormone Klotho improves the neurological deficits and prolongs life span in an experimental model with Amyotrophic Lateral Sclerosis (ALS).

A Boost of Klotho Protein Level Has Therapeutic Potential in Amyotrophic Lateral Sclerosis (ALS), Also Known as Lou Gehrig's Disease
scientists report that increasing the levels of the naturally occurring Klotho protein reduces the neurological deficits and prolongs life span in an experimental model of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

Is Klotho’s Partner FGF23 a Cognition Protein?
The longevity gene klotho keeps memory keen, but how? New research raises the possibility that it might influence cognition through its signaling partners FGF23 and the fibroblast growth factor (FGF) receptor.

Klogene and Boston University Scientists are First to use CRISPR for Activation of the Life Extension and Cognition Enhancing Klotho Gene
In a paper published today in Journal of Molecular Neuroscience, scientists from Klogene Therapeutics, Inc. and Boston University School of Medicine showed efficient transcriptional activation of the anti-aging multifunctional gene Klotho by CRISPR-dCas9.

Klogene Therapeutics, Inc. awarded a $1.49 Million grant for Alzheimers disease drug development
Klogene Therapeutics, Inc. today announced that it has been awarded a $1.49 Million small business innovation research grant (SBIR) by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). The funds from this award (number R44AG053084) will be used for the development of novel therapeutics for Alzheimer’s disease (AD) and other neurodegenerative diseases.